English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

β‐thalassemias result from diminished β‐globin synthesis and are associated with ineffective erythropoiesis and secondary iron overload caused by inappropriately low levels of the iron regulatory hormone hepcidin. The serine protease  TMPRSS6  attenuates hepcidin production in response to iron stores. Hepcidin induction reduces iron overload and mitigates anemia in murine models of β‐thalassemia intermedia. To further interrogate the efficacy of an RNAi‐therapeutic downregulating  Tmprss6 , β‐thalassemic  Hbb  th3/+  animals on an iron replete, an iron deficient, or an iron replete diet also containing the iron chelator deferiprone were treated with  Tmprss6  siRNA. We demonstrate that the total body iron burden is markedly improved in  Hbb  th3/+  animals treated with siRNA and chelated with oral deferiprone, representing a significant improvement compared to either compound alone. These data indicate that siRNA suppression of  Tmprss6 , in conjunction with oral iron chelation therapy, may prove superior for treatment of anemia and secondary iron loading seen in β‐thalassemia intermedia. Am. J. Hematol. 90:310–313, 2015. © 2015 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.

american journal of hematology

Combination therapy with a   T   mprss6   RNA i‐therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β‐thalassemia intermedia